Leukemia & Cell Therapy/Transplant faculty @CUHematology | Physician-scientist | Previously @PennCancer @PennIMResidents @UMNMSTP @DukeU
Denver, CO
Joined February 2018
- Tweets16
- Following181
- Followers120
- Likes46
Pleased to share our manuscript featured on the cover of @BloodPortfolio on CD2-targeting CART and CD2 signaling in CART. Great to work with @AlbertoCarturan @MarcoRuella and all to share this story - expanding targets for aggressive T cell neoplasms.
sciencedirect.com/science/ar…
New issue of Blood out now featuring Anti-CD2 CAR T-cells for T-cell neoplasms, Inflammatory landscape in clonal hematopoiesis, GRK5 variant linked to thrombotic disease, and more. Explore here: ashpublications.org/blood/is…
Pleased to share our results in @NatureMedicine using CAR-macrophages against solid tumors in this FIH trial. CAR-M were safe and showed tumor immunomodulatory activity in heavily pretreated pts. Great to work with @KReissMD and all authors! @PennCancer
Mat Angelos retweeted
Grateful to #ASH2024 for the chance to present our work on overcoming the absence of CD2:CD58 co-stimulation using an innovative PD1:iCD2 switch receptor. Thanks to my mentor @MarcoRuella and the @RuellaLab for their invaluable support. Excited to delve deeper into this approach!
Mat Angelos retweeted
Congrats to the now Dr. @_ruchipatel
for the publication of her PhD thesis in @SciImmunology. We show here that CD5 deletion enhances CART immunotherapy in multiple solid and liquid cancer models. @PennMedicine @RuellaLab science.org/doi/10.1126/scii… – at Philadelphia, PA
Congrats @PuneethGuru_ on leading this fantastic work. Looking forward to seeing this evolve into the clinic!
The main work of my PhD, truly a multi-team/disciplinary story, is out today in @NatImmunol. We show that the BTLA-HVEM immune checkpoint is enriched in the tumor microenvironment and blunts CAR T cell function. High BTLA in patient CART19 → poor outcome. nature.com/articles/s41590-0…
Mat Angelos retweeted
@Mat_Angelos from our @RuellaLab presenting for the for the first time a novem CD2 deleted CART2 for T-ALL: High preclinical efficacy against primary leukemias #ASH23 @PennMedicine – at San Diego, CA
Looking forward to speaking about our work on CD2-targeting CAR T at #ASH23. Please check it out Mon 315PM and to connect if interested! @MarcoRuella @_ruchipatel @PennCancer ash.confex.com/ash/2023/webp…
Check out some other novel CART strategies from @RuellaLab being presented and led by the talented @_ruchipatel and @PuneethGuru_ ash.confex.com/ash/2023/webp…. ash.confex.com/ash/2023/webp…. ash.confex.com/ash/2023/webp…
Check out some recent updates and our viewpoints for using CAR-T in T-cell leukemias/lymphomas. Great review to prep to #ASH23! @MarcoRuella @StefanBartaMD @_ruchipatel
sciencedirect.com/science/ar…
Check out our phase 1 CAR-M study in progress at the Developmental Therapeutics session Sunday AM. Excited to meet you at 327b and discuss other new cell therapy work at #ASCO2022 @KReissMD
🔬 Can macrophages be harnessed to #CARTherapy to fight solid tumors?
@KReissMD presents on a first-in-human study of the anti-HER2 CAR macrophage CT-0508 in patients with #HER2 overexpressing solid tumors: spr.ly/6017znKjJ
#ASCO22 #CARM
Check out our recent (open-access!) review on what's new in treating T-cell lymphomas. mdpi.com/1494870
Feel like there should be a greater emphasis on understanding when/how to implement appropriate statistical methods and improve study designs than just simply lowering the significance threshold...
The Proposal to Lower P Value Thresholds to .005 ja.ma/2HFzzye
Great approach for grad student training at Hopkins. Programming and bioinformatics work was some of the most creative and formative parts of my research; would be great to see this emphasized in more biological science programs. xitter.cf/nature/status/96651288…
Many doctoral curricula aim to produce narrowly focused researchers rather than critical thinkers. That can and must change, says Gundula Bosch go.nature.com/2Ew4qb9